Cheung AS, et al. - Authors sought to investigate if the adverse body composition changes improved after cessation of androgen deprivation therapy (ADT) given for prostate cancer. Findings demonstrated that metabolically adverse changes in body composition increased insulin resistance and reduced quality of life (QoL) persisted 2 years after ADT cessation. This, in turn, could be associated with incomplete testosterone recovery. It was determined that persisting adverse effects ought to be taken into account in the risk to benefit assessment of ADT. Furthermore, a continuation of proactive mitigation was recommended after cessation of treatment.